Europe PMC

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Prevalence of pretreatment HIV resistance to integrase inhibitors in West African and Southeast Asian countries.

Collaborators (35)

Author information

Affiliations

  • 1. MIVEGEC, Université de Montpellier, CNRS, IRD, Montpellier, France.
      Authors
    • Aghokeng AF 1
    • Ngo-Giang-Huong N 1
    (2 authors)
  • 2. HIV/AIDS Laboratory, Pasteur Institute, Ho Chi Minh City, Vietnam.
      Authors
    • Huynh THK 2
    (1 author)
  • 3. Faculté des Sciences de la Santé, Centre de Biologie Moléculaire et d'Immunologie, Université de Lomé, Lomé, Togo.
      Authors
    • Dagnra AY 3
    (1 author)
  • 4. Programme PACCI, Virology Laboratory CIRBA, Abidjan, Côte d'Ivoire.
      Authors
    • D'Aquin Toni T 4
    (1 author)
  • 5. UCRC/SEREFO, FMOS, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.
      Authors
    • Maiga AI 5
    (1 author)
    • Show all (10)

ORCIDs linked to this article

The Journal of Antimicrobial Chemotherapy, 01 May 2024, 79(5):1164-1168
https://doi.org/10.1093/jac/dkae087 PMID: 38546752 

Abstract 

Objectives

Integrase strand transfer inhibitors (INSTIs) have been recently recommended as the preferred first-line option for antiretroviral treatment initiators in low- and middle-income countries (LMICs) in response to the growing circulation of resistant HIV to non-nucleoside reverse transcriptase inhibitors (NNRTIs). In this study, we estimated the frequency of pretreatment drug resistance (PDR) to INSTIs in West Africa and Southeast Asia.

Materials and methods

Using samples collected from 2015 to 2016, and previously used to assessed PI, NRTI and NNRTI resistance, we generated HIV integrase sequences and identified relevant INSTI PDR mutations using the Stanford and ANRS algorithms.

Results

We generated 353 integrase sequences. INSTI PDR frequency was low, 1.1% (4/353) overall, ranging from 0% to 6.3% according to country. However, frequency of PDR to any drug class was very high, 17.9% (95% CI: 13.9%-22.3%), and mostly associated with a high level of NNRTI PDR, 9.7%, and a moderate level of NRTI PDR, 5.3%.

Conclusions

Our results support the recent introduction of INSTIs in LMICs to improve treatment outcome in these settings, but also stress the need for effective actions to prevent uncontrolled emergence of drug resistance to this drug class.

Full text links 

Read article at publisher's site: https://doi.org/10.1093/jac/dkae087

Citations & impact 

Impact metrics

1
Citation
Jump to Citations

Article citations

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.

Funding 

Funders who supported this work.

National Agency for research on AIDS and Viral Hepatitis (1)